Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α

Olefsky, 1985, Mechanisms of insulin resistance in noninsulin-dependent (type II) diabetes, Am. J. Med., 79, 12, 10.1016/S0002-9343(85)80003-6 Olefsky, 1995, Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms, Am. J. Clin. Nutr., 61, 980S, 10.1093/ajcn/61.4.980S Arner, 2002, Insulin resistance in type 2 diabetes: role of fatty acids, Diabetes Metab. Res. Rev., 18, S5, 10.1002/dmrr.254 Lebovitz, 2001, Insulin resistance: definition and consequences, Exp. Clin. Endocrinol. Diabetes, 109, S135, 10.1055/s-2001-18576 Reaven, 1993, Role of insulin resistance in human disease (syndrome X): an expanded definition, Annu. Rev. Med., 44, 121, 10.1146/annurev.me.44.020193.001005 Reaven, 1995, Pathophysiology of insulin resistance in human disease, Physiol. Rev., 75, 473, 10.1152/physrev.1995.75.3.473 Saltiel, 1996, Thiazolidinediones in the treatment of insulin resistance and type II diabetes, Diabetes, 45, 1661, 10.2337/diabetes.45.12.1661 Lebovitz, 2001, Insulin resistance and its treatment by thiazolidinediones, Recent Prog. Horm. Res., 56, 265, 10.1210/rp.56.1.265 Olefsky, 2000, PPARγ and the treatment of insulin resistance, Trends Endocrinol. Metab., 11, 362, 10.1016/S1043-2760(00)00306-4 Stumvoll, 2002, Glitazones: clinical effects and molecular mechanisms, Ann. Med., 34, 217, 10.1080/713782132 Stumvoll, 2001, Insulin resistance and insulin sensitizers, Horm. Res., 55, 3, 10.1159/000063466 DeFronzo, 1992, Pathogenesis of NIDDM. A balanced overview, Diabetes Care, 15, 318, 10.2337/diacare.15.3.318 Kitamura, 2003, Insulin receptor knockout mice, Annu. Rev. Physiol., 65, 313, 10.1146/annurev.physiol.65.092101.142540 Mauvais-Jarvis, 2002, Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance, Clin. Endocrinol. (Oxf.), 57, 1, 10.1046/j.1365-2265.2002.01563.x Bluher, 2002, Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance, Dev. Cell, 3, 25, 10.1016/S1534-5807(02)00199-5 Guerra, 2001, Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance, J. Clin. Invest., 108, 1205, 10.1172/JCI13103 Michael, 2000, Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction, Mol. Cell, 6, 87, 10.1016/S1097-2765(00)00010-1 Kulkarni, 1999, Tissuespecific knockout of the insulin receptor in pancreatic-β cells creates an insulin secretory defect similar to that in type 2 diabetes, Cell, 96, 329, 10.1016/S0092-8674(00)80546-2 Bruning, 1998, A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance, Mol. Cell, 2, 559, 10.1016/S1097-2765(00)80155-0 Bruning, 2000, Role of brain insulin receptor in control of body weight and reproduction, Science, 289, 2122, 10.1126/science.289.5487.2122 Kennedy, 2000, Protein tyrosine phosphatase-1B in diabetes, Biochem. Pharmacol., 60, 877, 10.1016/S0006-2952(00)00305-1 Jiang, 2002, Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes, Front Biosci., 7, d903, 10.2741/jiang Kahn, 1996, Lilly lecture 1995. Glucose transport: pivotal step in insulin action, Diabetes, 45, 1644, 10.2337/diabetes.45.11.1644 White, 2002, IRS proteins and the common path to diabetes, Am. J. Physiol. Endocrinol. Metab., 283, E413, 10.1152/ajpendo.00514.2001 Goldstein, 2002, Insulin resistance as the core defect in type 2 diabetes mellitus, Am. J. Cardiol., 90, 3G, 10.1016/S0002-9149(02)02553-5 Trayhurn, 2001, Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ, Proc. Nutr. Soc., 60, 329, 10.1079/PNS200194 DeFronzo, 1985, Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus, J. Clin. Invest., 76, 149, 10.1172/JCI111938 Martin, 1992, Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study, Lancet, 340, 925, 10.1016/0140-6736(92)92814-V Lillioja, 1993, Insulin resistance and insulin secretory dysfunction as 24 precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians, N Engl. J. Med., 329, 1988, 10.1056/NEJM199312303292703 Yu, 2002, Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle, J. Biol. Chem., 277, 50230, 10.1074/jbc.M200958200 Kruszynska, 2002, Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation, J. Clin. Endocrinol. Metab., 87, 226, 10.1210/jc.87.1.226 Boden, 1994, Mechanisms of fatty acid-induced inhibition of glucose uptake, J. Clin. Invest, 93, 2438, 10.1172/JCI117252 Staehr, 2003, Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis, Diabetes, 52, 260, 10.2337/diabetes.52.2.260 Laws, 1996, Free fatty acids, insulin resistance and lipoprotein metabolism, Curr. Opin. Lipidol., 7, 172, 10.1097/00041433-199606000-00011 Saxena, 1989, Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids, J. Biol. Chem., 264, 4349, 10.1016/S0021-9258(18)83748-6 Shimabukuro, 1998, Fatty acid-induced-β cell apoptosis: a link between obesity and diabetes, Proc. Natl. Acad. Sci. U.S.A., 95, 2498, 10.1073/pnas.95.5.2498 Ruan, 2002, Profiling gene transcription in vivo reveals adipose tissue as an immediate target of TNF-α: implications for insulin resistance, Diabetes, 51, 3176, 10.2337/diabetes.51.11.3176 Carswell, 1975, An endotoxininduced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. U.S.A., 72, 3666, 10.1073/pnas.72.9.3666 Beutler, 1985, Identity of tumour necrosis factor and the macrophage-secreted factor cachectin, Nature, 316, 552, 10.1038/316552a0 Kawakami, 1982, Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells, Proc. Natl. Acad. Sci. U.S.A., 79, 912, 10.1073/pnas.79.3.912 Kawakami, 1981, Studies of endotoxin-induced decrease in lipoprotein lipase activity, J. Exp. Med., 154, 631, 10.1084/jem.154.3.631 Tracey, 1986, Shock and tissue injury induced by recombinant human cachectin, Science, 234, 470, 10.1126/science.3764421 Tracey, 1988, Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation, J. Exp. Med., 167, 1211, 10.1084/jem.167.3.1211 Kriegler, 1988, A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF, Cell, 53, 45, 10.1016/0092-8674(88)90486-2 Maskos, 1998, Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme, Proc. Natl. Acad. Sci. U.S.A., 95, 3408, 10.1073/pnas.95.7.3408 Black, 1997, A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells, Nature, 385, 729, 10.1038/385729a0 Wallach, 1999, Tumor necrosis factor receptor and Fas signaling mechanisms, Annu. Rev. Immunol., 17, 331, 10.1146/annurev.immunol.17.1.331 Hotamisligil, 1993, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126/science.7678183 Hotamisligil, 1995, Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance, J. Clin. Invest., 95, 2409, 10.1172/JCI117936 Montague, 1998, Depot-related gene expression in human subcutaneous and omental adipocytes, Diabetes, 47, 1384, 10.2337/diabetes.47.9.1384 Kern, 1995, The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase, J. Clin. Invest, 95, 2111, 10.1172/JCI117899 Hotamisligil, 1994, Tumor necrosis factor-α inhibits signaling from the insulin receptor, Proc. Natl. Acad. Sci. U.S.A., 91, 4854, 10.1073/pnas.91.11.4854 Lang, 1992, Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output, Endocrinology, 130, 43, 10.1210/en.130.1.43 Hotamisligil, 1994, Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α, J. Clin. Invest, 94, 1543, 10.1172/JCI117495 Uysal, 1997, Protection from obesityinduced insulin resistance in mice lacking TNF-α function, Nature, 389, 610, 10.1038/39335 Uysal, 1998, Functional analysis of tumor necrosis factor (TNF) receptors in TNF-α-mediated insulin resistance in genetic obesity, Endocrinology, 139, 4832, 10.1210/en.139.12.4832 Ofei, 1996, Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM, Diabetes, 45, 881, 10.2337/diabetes.45.7.881 Randle, 1963, The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, 1, 785, 10.1016/S0140-6736(63)91500-9 Randle, 1965, The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus, Ann. N Y Acad. Sci., 131, 324, 10.1111/j.1749-6632.1965.tb34800.x Boden, 1991, Effects of fat on insulin-stimulated carbohydrate metabolism in normal men, J. Clin. Invest, 88, 960, 10.1172/JCI115399 Bogardus, 1984, Correlation between muscle glycogen synthase activity and in vivo insulin action in man, J. Clin. Invest, 73, 1185, 10.1172/JCI111304 Shulman, 1990, Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy, N Engl. J. Med., 322, 223, 10.1056/NEJM199001253220403 Saloranta, 1991, Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulindependent) diabetes mellitus, Diabetologia, 34, 409, 10.1007/BF00403179 Ruderman, 1969, Role of free fatty acids in glucose homeostasis, Arch Intern Med., 123, 299, 10.1001/archinte.123.3.299 Byrne, 1991, Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells, Biochem. J., 280, 99, 10.1042/bj2800099 Byrne, 1992, Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin, Biochem. J., 288, 101, 10.1042/bj2880101 Dixon, 1993, Regulation of hepatic secretion of apolipoprotein Bcontaining lipoproteins: information obtained from cultured liver cells, J. Lipid Res., 34, 167, 10.1016/S0022-2275(20)40744-8 Boden, 1996, Fatty acids and insulin resistance, Diabetes Care, 19, 394, 10.2337/diacare.19.4.394 Roden, 1996, Mechanism of free fatty acid-induced insulin resistance in humans, J. Clin. Invest, 97, 2859, 10.1172/JCI118742 Ferrannini, 1983, Effect of fatty acids on glucose production and utilization in man, J. Clin. Invest, 72, 1737, 10.1172/JCI111133 Reaven, 1988, Lowering of plasma glucose in diabetic rats by antilipolytic agents, Am. J. Physiol., 254, E23 Reaven, 1988, Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocininduced diabetes, Diabetes, 37, 28, 10.2337/diabetes.37.1.28 Balasse, 1973, Influence of nicotinic acid on the rates of turnover and oxidation of plasma glucose in man, Metabolism, 22, 1193, 10.1016/0026-0495(73)90207-2 Boden, 1998, Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects, Diabetes, 47, 1609, 10.2337/diabetes.47.10.1609 Bonadonna, 1990, Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans, Am. J. Physiol., 259, E736 Swislocki, 1987, Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (noninsulin-dependent) diabetes, Diabetologia, 30, 622, 10.1007/BF00277318 Skowronski, 1991, Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes, Diabet. Med., 8, 330, 10.1111/j.1464-5491.1991.tb01605.x Laws, 1997, Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators, Arterioscler. Thromb. Vasc. Biol., 17, 64, 10.1161/01.ATV.17.1.64 Lavoie, 1993, Increased insulin suppression of plasma free fatty acid concentration in exercise-trained rats, J. Appl. Physiol., 74, 293, 10.1152/jappl.1993.74.1.293 Chen, 1987, Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 64, 17, 10.1210/jcem-64-1-17 Stralfors, 1984, Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin, Proc. Natl. Acad. Sci. U.S.A., 81, 3317, 10.1073/pnas.81.11.3317 Stralfors, 1989, Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity, Eur. J. Biochem., 182, 379, 10.1111/j.1432-1033.1989.tb14842.x Jensen, 1989, Insulin regulation of lipolysis in nondiabetic and IDDM subjects, Diabetes, 38, 1595, 10.2337/diabetes.38.12.1595 Campbell, 1992, Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification, Am. J. Physiol., 263, E1063 Elks, 1985, Antilipolytic action of insulin: role of cAMP phosphodiesterase activation, Endocrinology, 116, 2119, 10.1210/endo-116-5-2119 Belfrage, 1985, Molecular mechanisms for hormonal control of adipose tissue lipolysis, Int. J. Obes., 9, 129 Belfrage, 1981, Regulation of adipose-tissue lipolysis by phosphorylation of hormone-sensitive lipase, Int. J. Obes., 5, 635 Igal, 2001, Mitochondrial glycerol phosphate acyltransferase directs the incorporation of exogenous fatty acids into triacylglycerol, J. Biol. Chem., 276, 42205, 10.1074/jbc.M103386200 Ruan, 2001, Overexpression of 1-acyl-glycerol-3-phosphate acyltransferase-α enhances lipid storage in cellular models of adipose tissue and skeletal muscle, Diabetes, 50, 233, 10.2337/diabetes.50.2.233 Scherer, 1995, A novel serum protein similar to C1q, produced exclusively in adipocytes, J. Biol. Chem., 270, 26746, 10.1074/jbc.270.45.26746 Nakano, 1996, Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma, J. Biochem. (Tokyo), 120, 803, 10.1093/oxfordjournals.jbchem.a021483 Maeda, 1996, cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1), Biochem. Biophys. Res. Commun., 221, 286, 10.1006/bbrc.1996.0587 Hu, 1996, AdipoQ is a novel adipose-specific gene dysregulated in obesity, J. Biol. Chem., 271, 10697, 10.1074/jbc.271.18.10697 Berg, 2002, ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism, Trends Endocrinol. Metab., 13, 84, 10.1016/S1043-2760(01)00524-0 Shapiro, 1998, The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor, Curr. Biol., 8, 335, 10.1016/S0960-9822(98)70133-2 Bogan, 2001, Insulin-responsive compartments containing GLUT4 in 3T3-L1 and CHO cells: regulation by amino acid concentrations, Mol Cell Biol., 21, 4785, 10.1128/MCB.21.14.4785-4806.2001 Ruan, 2002, Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory, Diabetes, 51, 1319, 10.2337/diabetes.51.5.1319 Arita, 1999, Paradoxical 33 decrease of an adipose-specific protein, adiponectin, in obesity, Biochem. Biophys. Res. Commun., 257, 79, 10.1006/bbrc.1999.0255 Combs, 2002, Induction of adipocyte complement-related protein of 30 kDa by PPARγ agonists: a potential mechanism of insulin sensitization, Endocrinology, 143, 998, 10.1210/en.143.3.998 Fruebis, 2001, Proteolytic cleavage product of 30 kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc. Natl. Acad. Sci. U.S.A., 98, 2005, 10.1073/pnas.041591798 Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat. Med., 8, 1288, 10.1038/nm788 Tomas, 2002, Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation, Proc. Natl. Acad. Sci. U.S.A., 99, 16309, 10.1073/pnas.222657499 Combs, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J. Clin. Invest, 108, 1875, 10.1172/JCI14120 Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat. Med., 7, 947, 10.1038/90992 Kubota, 2002, Disruption of adiponectin causes insulin resistance and neointimal formation, J. Biol. Chem., 277, 25863, 10.1074/jbc.C200251200 Maeda, 2002, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat. Med., 8, 731, 10.1038/nm724 Ma, 2002, Increased β-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin, J. Biol. Chem., 277, 34658, 10.1074/jbc.C200362200 Pajvani, 2003, Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity, J. Biol. Chem., 278, 9073, 10.1074/jbc.M207198200 Hotamisligil, 1996, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance, Science, 271, 665, 10.1126/science.271.5249.665 Yuan, 2001, Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ, Science, 293, 1673, 10.1126/science.1061620 Tamori, 2002, Role of peroxisome proliferatoractivated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes, Diabetes, 51, 2045, 10.2337/diabetes.51.7.2045 Ruan, 2003, Troglitazone antagonizes TNF-α-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kB, J Biol Chem, 278, 28181, 10.1074/jbc.M303141200